• Skip to main content
  • Skip to primary sidebar
Transfusion News
  • About Us
  • Topics
    • Adverse Events (non-infectious)
    • Blood Donation
    • Cell Therapy
    • Coagulation & Plasma Transfusion
    • Platelet Transfusion
    • Policy and Guidelines
    • Quality Control and Regulatory
    • RBC Transfusion
    • Serology/Genotyping
    • Special Transfusion Situations
    • Transfusion Transmitted Infections
  • Continuing Education
  • Archives
  • Podcasts
  • Question of the Day
  • Search
  • Subscribe to Email Alerts
  • Follow us on
  • Search
  • Subscribe to Email Alerts

VIDEO: Reducing TRALI Risk

December 15, 2014

Today we will be discussing TRALI, or transfusion-related acute lung injury. TRALI accounts for almost half of all transfusion-related fatalities in the United States.

Although several mechanisms exist, one of the major causes of TRALI is donor antibodies to white blood cells, such as human leukocyte antigen and human neutrophil antigen, or commonly referred to as HLA and HNA.

Dr. AuBuchon who wrote an editorial in TRANSFUSION comments:

“Blood collectors in the United States have taken steps over the last half-dozen years to reduce the risk of TRALI through plasma, and, in many cases, also apheresis platelets. This has primarily involved women who have previously been pregnant, either deferring the use of their plasma or testing them to identify those lacking HLA antibodies. These steps have resulted in a reduction of TRALI risk by about three-quarters.”

Dr. Vandekerckhove and his colleagues in Belgium screened 77 male plateletpheresis donors with a history of transfusions and 942 female donors. Overall, 20.2% of the donors had HLA antibodies.

Here is Dr. Vandekerckhove with the major findings of the study:

“Our study indicates that a history of transfusion is a minor risk factor for immunization against HLA antigens, but in contrast, former pregnancies constitute a major risk factor for the development of HLA antibodies.”

Further research is needed to fully understand novel treatments to attenuate TRALI.

Again, here is Dr. AuBuchon:

“We also have yet to devise a simple, effective and uniform approach to donor management in TRALI cases. Development of such a system is hampered by the recognition that TRALI is a bedside—not a laboratory—diagnosis, and some units that cause what we call TRALI do not have any HLA or HNA antibodies.”

A recently published paper in BLOOD, examined the therapeutic effects of aspirin and aspirin-triggered lipoxin in mice with TRALI. Whether the same treatments can be used successfully in human patients awaits further research.

We’ll be back with another edition of Transfusion News after the holidays on January 15th. Thanks for joining us.

References

1. AuBuchon J. TRALI: reducing its risk while trying to understand its causes. Transfusion 2014;54:3021-3025.
2. De Clippel D, Baeten M, Torfs A, Emonds MP, Feys HB, Compernolle V, Vandekerckhove P. Screening for HLA antibodies in plateletpheresis donors with a history of transfusion or pregnancy. Transfusion 2014. doi: 10.1111/trf.12727
3. Ortiz-Munoz G, Mallavia B, Bins A, Headley M, Krummel MF, Looney MR. Aspirin-triggered 15-epi-lipoxin A4 regulates neutrophil-platelet aggregation and attenuates acute lung injury in mice. Blood 2014;124: 2625-34.
4. Zimring JC. The fat and the skinny on acute lung injury. Blood 2014;124: 2617-8.

 

Transfusion News would like to learn a bit more about its audience to help provide you with  the most helpful content. Please complete our reader survey for a chance to win a $100 Amazon gift card. 

 

 

Filed Under

  • Adverse Events (non-infectious)
  • Featured
  • Videos

Recommended

  • VIDEO: Telltale Signs of Progress in the Management of Thrombotic Thrombocytopenic Purpura

  • VIDEO: Implementation of Pathogen Reduction in the United States

  • VIDEO: RBC Transfusion Complications in Thalassemia Patients

Show Comments

Comments on this article are closed.

Get the latest news. Subscribe to our mailing list. Sign Up

Primary Sidebar

Latest News

  • New Erythropoietin Gene Variants Linked to Hereditary Erythrocytosis

  • Multifaceted Threats to the Blood Supply from Climate Change

  • Distinct Roles for Differently Aged Platelets

  • Anemia Treatment Bundle Improves Hemoglobin Recovery after Critical Illness

    Question of the Day

    Copyright © 2025 John Wiley & Sons, Inc. All Rights Reserved.
    Privacy Policy

    Association for the Advancement of Blood and Biotherapies Wiley